35th Hemophilia Symposium Hamburg 2004 /
Motion analysis as introduced 2 years ago on a national basis effectively identifies individual functional disorders and provides a means for describing them on the basis of a score. Individual therapy planning is possible. More treatment tends to produce better function scores and thus helps to low...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | , |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Berlin, Heidelberg :
Springer Berlin Heidelberg,
2006.
|
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Epidemiology
- HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 2003/2004 Survey)
- Hemophilia Registry of the Medical Committee of the Swiss Hemophilia Association — Update and Annual Survey 2004
- Risk of Infections and Inhibitors in Hemophilia
- Update on the Safety of Clotting Factors, Mainly Regarding the Risk of Transmission of vCJD (Variant Creutzfeldt Jakob Disease)
- nvCJD and Blood Products in the UK
- Mutation Type Dependent Inhibitor Risk — a Single Center Study on 432 Patients with Severe Hemophilia A
- Inhibitor Incidence in Previously Untreated Patients (PUPs) with Hemophilia A and B. A Prospective Multi-Center Study of the Pediatric Committee of the German, Swiss and Austrian Society for Thrombosis and Hemostasis Research (GTH)
- ADVATE Inhibitor Risk Profile: 18 Months post-Licensure
- EACH-Registry: An European Registry for Acquired Hemophilia
- Elective Orthopedic Surgery for Hemophilia Patients with Inhibitors
- Chronic Synovitis and Long-term Results of Orthopedic Treatment
- Results after Total Knee and Hip Replacement in Patients with Hemophilia A — A Single Center Experience
- Motion Analysis Epidemiology in Hemophilic Children
- Radiosynoviorthesis in Hemophilic Arthropathy — A Single Center Experience
- Laboratory Diagnostics: Coagulation Factor, Inhibitors, Monitoring
- Individual Therapy of Hemophilia — New Laboratory Methods Considering Platelets
- Epitope Mapping during FVIII Inhibitor Elimination with Rituximab Reveals Conformational Epitopes on FVIII and Identifies Small Molecules Blocking Inhibitor and Targeting B Cells
- Lack of Factor VIII Expression Represents a Novel Mechanism Leading to Hemophilia A
- Pediatric Hemostaseology
- Effects of the Factor V G1691 A Mutation and the Factor II G20210A Variant on the Clinical Expression of Severe Hemophilia A (< 2%) in Children — Results of a Multicenter Study
- Continuous Infusion of Factor Concentrates in Children with Hemophilia A in Comparison to Bolus Injections
- Decreased Clotting Factor Activity (VIII, IX, XI, and XII) due to Inhibitors with Lupus-like Activity in Childhood
- Free Lectures
- Effect of Activated Recombinant Coagulation Factor VII on the Function of Glycoprotein IIb/IIIa-Inhibited Platelets in Vitro
- Mutation Analysis in Hereditary Angioedema Identifies Patients at Risk for Developing Acute and Life Threatening Edema
- Recurrent Mutation in ADAMTS13 Gene as a Cause of a Hereditary Thrombotic Thrombocytopenic Purpura in the Czech Republic
- Clinical Manifestations of Patients with Dysfibrinogenemia
- Case Report of a FXIII Inhibitor in a 77-year-old Patient
- Poster
- The ABC’s of Hemophilia
- The Long Journey to Being Diagnosed as a Carrier of Hemophilia A — A Woman with Abnormally Prolonged Bleeding after Myocardial Infarction
- Clinical Investigation of Orthopedic Outcome in Patients with Severe Hemophilia — Advantage of an Early Prophylactic Treatment?
- The Relevance of Thrombophilic Risk Factors on Bleeding Tendency in Hemophilia A Patients
- Magnetic Field Therapy in Patients with Severe Hemophilia — Motion Analysis and Quality Control
- The Clinical Course of two Patients Receiving High Dose Factor VIII — Replacement Therapy
- Determination of the Factor VIII Plasma Activity of Hemophilia A Patients Treated with a New Recombinant Factor VIII Concentrate
- Socio-Economic Aspects of Hemophilia Treatment in Romania
- Immunosuppressive Treatment in Acquired von-Willebrand’s Syndrome
- HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A Retrospective Study: Medical Aspects
- HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A Retrospective Study: Psychosocial Aspects
- Testing Factor VIII Activity by Using the Chromogenic Assay in Carriers of Hemophilia A
- Hip Replacement in Hemophilic Patients — A 30 Years Single Center Experience
- Successful Therapy with anti CD20 Monoclonal Antibody Rituximab in Patients with Acquired Hemophilia against Factor VIII
- Unusual Prolonged Course of an Immune Tolerance Therapy (ITT) in a Patient with Severe Hemophilia A and a High-Titer Inhibitor Development
- Successful Major Surgery with Minimal Dosage of rFVIIa in a Hemophilia A Patient with High Level of Alloantibodies to Factor VIII
- Inhibitor Development after Continuous Infusion of Factor VIII: A Retrospective Study in Germany
- Inhibitors in PTP’S: A Retrospective Study in Germany
- Elective Orthopedic Surgery in Inhibitor Patients — the Frankfurt Concept
- The Frequency of Venous Thromboembolism in Women with FV Leiden in Association with Pregnancy and Puerperium
- Spectrum of Molecular Defects and Mutation Detection Date in Patients with Severe Hemophilia A
- Hemophilia Patients and Prothrombotic Gene Mutation
- ?A1a82Gly Represents a Common Fibrinogen Chain Variant in Caucasians
- A Novel Mutation (Asp36Tyr) in the Vitamin K Epoxide Reductase Complex Subunit 1 Gene (VKORC1) Causes Increased Phenprocoumon Requirement
- Denaturing High Performance Liquid Chromatography Represents an Efficient Technique for Detection of Heterozygous Large Deletions in Antithrombin Gene
- Recurrent Coronary Stent Thrombosis in a Patient with Combined Aspirin and Clopidogrel Resistance
- Coagulation Factor XIII Mutation Profile: Update 2004
- Site-Directed Mutagenesis of VKORC1, the Target Protein of Coumarin-Type Anticoagulants
- Treatment of Dilution Coagulopathy by Fibrinogen and Platelet Concentrates
- Pathogenesis of Hepatic Veno-Occlusive Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation.
